Literature DB >> 19150171

Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma.

Grégoire Robert1, Grégoire Gabbay, Raphaël Bram, Hervé Wallerand, Colette Deminière, François Cornelis, Jean-Christophe Bernhard, Alain Ravaud, Philippe Ballanger.   

Abstract

The authors present the first case report of complete histologic remission after neoadjuvant sunitinib treatment on primary renal tumour and vena cava thrombus. A 78-yr-old woman with an Eastern Cooperative Oncology Group (ECOG) score of 0 presented with a T3b renal tumour. She refused surgical treatment but agreed to percutaneous biopsy and medical treatment. A Fuhrman III renal cell carcinoma was histologically confirmed on percutaneous biopsy, and sunitinib treatment was administered over 6 mo. A significant objective response was observed for tumour size and thrombus. The patient finally accepted surgical treatment. Pathologic examination concluded with a complete response of primary tumour and thrombus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19150171     DOI: 10.1016/j.eururo.2008.12.036

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  15 in total

Review 1.  Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?

Authors:  Adrian Husillos Alonso; Manuel Carbonero García; Carmen González Enguita
Journal:  World J Nephrol       Date:  2015-05-06

2.  Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial.

Authors:  Jose A Karam; Catherine E Devine; Bryan M Fellman; Diana L Urbauer; E Jason Abel; Mohamad E Allaf; Axel Bex; Brian R Lane; R Houston Thompson; Christopher G Wood
Journal:  BJU Int       Date:  2015-06-29       Impact factor: 5.588

Review 3.  The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies.

Authors:  Pierre Bigot; Souhil Lebdai; Alain Ravaud; Abdel Rahmène Azzouzi; Jean-Marie Ferrière; Jean-Jacques Patard; Jean-Christophe Bernhard
Journal:  World J Urol       Date:  2013-03-30       Impact factor: 4.226

4.  Neoadjuvant targeted therapy in a primary metastasized renal cell cancer patient leads to down-staging of inferior vena cava thrombus (IVC) enabling a cardiopulmonary bypass-free tumor nephrectomy: a case report.

Authors:  Inga Peters; Michael Winkler; Björn Jüttner; Omke E Teebken; T R Herrmann; Christoph von Klot; Mario Kramer; Angela Reichelt; Mahmoud Abbas; Markus A Kuczyk; Axel S Merseburger
Journal:  World J Urol       Date:  2012-09-30       Impact factor: 4.226

5.  Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma.

Authors:  Hironori Fukuda; Tsunenori Kondo; Toshio Takagi; Jumpei Iizuka; Yoji Nagashima; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2017-04-01       Impact factor: 3.402

6.  Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?

Authors:  Pierre Bigot; Tarek Fardoun; Jean Christophe Bernhard; Evanguelos Xylinas; Julien Berger; Morgan Rouprêt; Jean-Baptiste Beauval; Samuel Lagabrielle; Souhil Lebdai; Myriam Ammi; Hervé Baumert; Bernard Escudier; Nicolas Grenier; Jean-François Hétet; Jean-Alexandre Long; Philippe Paparel; Nathalie Rioux-Leclercq; Michel Soulié; Abdel-Rahmène Azzouzi; Karim Bensalah; Jean-Jacques Patard
Journal:  World J Urol       Date:  2013-04-27       Impact factor: 4.226

7.  Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.

Authors:  C Lance Cowey; Chirag Amin; Raj S Pruthi; Eric M Wallen; Matthew E Nielsen; Gayle Grigson; Cathy Watkins; Keith V Nance; Jeffrey Crane; Mark Jalkut; Dominic T Moore; William Y Kim; Paul A Godley; Young E Whang; Julia R Fielding; W Kimryn Rathmell
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

Review 8.  The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma.

Authors:  Leonardo D Borregales; Mehrad Adibi; Arun Z Thomas; Christopher G Wood; Jose A Karam
Journal:  Ther Adv Urol       Date:  2015-11-20

9.  Neo adjuvant treatment with targeted molecules for renal cell cancer in current clinical practise.

Authors:  Ginil Kumar Pooleri; Tiyadath Balagopalan Nair; Kalavampara V Sanjeevan; Appu Thomas
Journal:  Indian J Surg Oncol       Date:  2011-11-17

10.  Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.

Authors:  Craig Labbate; Ken Hatogai; Ryan Werntz; Walter M Stadler; Gary D Steinberg; Scott Eggener; Randy F Sweis
Journal:  J Immunother Cancer       Date:  2019-03-11       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.